Ra Capital Management as of March 31, 2021
Portfolio Holdings for Ra Capital Management
Ra Capital Management holds 82 positions in its portfolio as reported in the March 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 12.5 | $826M | 6.4M | 128.88 | |
| Novavax Com New (NVAX) | 8.2 | $544M | 3.0M | 181.31 | |
| Vor Biopharma (VOR) | 7.2 | $479M | 11M | 43.10 | |
| Atea Pharmaceuticals (AVIR) | 5.0 | $332M | 5.4M | 61.75 | |
| Forma Therapeutics Hldgs SHS | 3.8 | $253M | 9.0M | 28.02 | |
| Tg Therapeutics (TGTX) | 3.4 | $224M | 4.6M | 48.20 | |
| Nkarta (NKTX) | 2.8 | $184M | 5.6M | 32.90 | |
| Chemocentryx | 2.7 | $182M | 3.6M | 51.24 | |
| Macrogenics (MGNX) | 2.4 | $157M | 4.9M | 31.85 | |
| Iteos Therapeutics (ITOS) | 2.3 | $151M | 4.4M | 34.18 | |
| ImmunoGen | 2.2 | $149M | 18M | 8.10 | |
| Travere Therapeutics (TVTX) | 2.1 | $140M | 5.6M | 24.97 | |
| Instil Bio | 1.8 | $122M | 4.9M | 25.08 | |
| Phathom Pharmaceuticals (PHAT) | 1.8 | $117M | 3.1M | 37.56 | |
| 89bio (ETNB) | 1.7 | $112M | 4.7M | 23.68 | |
| Kinnate Biopharma (KNTE) | 1.7 | $112M | 3.6M | 31.16 | |
| Rhythm Pharmaceuticals (RYTM) | 1.6 | $104M | 4.9M | 21.27 | |
| Zogenix Com New | 1.6 | $103M | 5.3M | 19.52 | |
| Axsome Therapeutics (AXSM) | 1.4 | $94M | 1.7M | 56.62 | |
| Rocket Pharmaceuticals (RCKT) | 1.4 | $94M | 2.1M | 44.37 | |
| Adverum Biotechnologies | 1.4 | $92M | 9.4M | 9.86 | |
| Edgewise Therapeutics (EWTX) | 1.3 | $85M | 2.6M | 32.50 | |
| Curis Com New | 1.2 | $81M | 7.1M | 11.32 | |
| Bolt Biotherapeutics (BOLT) | 1.2 | $78M | 2.4M | 32.91 | |
| Vaxcyte (PCVX) | 1.2 | $76M | 3.9M | 19.75 | |
| Seres Therapeutics (MCRB) | 1.1 | $76M | 3.7M | 20.59 | |
| Silverback Therapeutics (SPRY) | 1.1 | $76M | 1.7M | 43.63 | |
| Igm Biosciences (IGMS) | 1.1 | $75M | 983k | 76.69 | |
| Kala Pharmaceuticals | 1.1 | $73M | 11M | 6.74 | |
| Olema Pharmaceuticals (OLMA) | 1.1 | $71M | 2.2M | 33.18 | |
| Orchard Therapeutics Ads | 1.0 | $69M | 12M | 5.62 | |
| Solid Biosciences | 1.0 | $68M | 12M | 5.53 | |
| Design Therapeutics (DSGN) | 1.0 | $65M | 2.2M | 29.90 | |
| Black Diamond Therapeutics (BDTX) | 0.9 | $63M | 2.6M | 24.26 | |
| Trillium Therapeutics Com New | 0.9 | $57M | 5.3M | 10.74 | |
| Pmv Pharmaceuticals (PMVP) | 0.8 | $56M | 1.7M | 32.89 | |
| Connect Biopharma Hldgs Ads (CNTB) | 0.8 | $55M | 3.0M | 18.50 | |
| Constellation Pharmceticls I | 0.8 | $52M | 2.2M | 23.39 | |
| C4 Therapeutics Com Stk (CCCC) | 0.8 | $51M | 1.4M | 36.99 | |
| Sutro Biopharma (STRO) | 0.7 | $48M | 2.1M | 22.76 | |
| Geron Corporation (GERN) | 0.7 | $48M | 30M | 1.58 | |
| Wave Life Sciences SHS (WVE) | 0.7 | $44M | 7.8M | 5.61 | |
| Dyne Therapeutics (DYN) | 0.7 | $44M | 2.8M | 15.53 | |
| Verona Pharma Sponsored Ads (VRNA) | 0.6 | $43M | 5.1M | 8.36 | |
| Ardelyx (ARDX) | 0.6 | $40M | 6.1M | 6.62 | |
| Inozyme Pharma (INZY) | 0.6 | $40M | 2.0M | 19.80 | |
| Satsuma Pharmaceuticals Ord | 0.5 | $35M | 5.9M | 5.91 | |
| Relay Therapeutics (RLAY) | 0.5 | $35M | 1.0M | 34.57 | |
| Akouos | 0.5 | $32M | 2.3M | 13.87 | |
| Cerevel Therapeutics Hldng I (CERE) | 0.5 | $30M | 2.2M | 13.73 | |
| Cytomx Therapeutics (CTMX) | 0.4 | $27M | 3.5M | 7.73 | |
| Achilles Therapeutics Sponsored Ads (ACHL) | 0.3 | $23M | 1.4M | 16.55 | |
| Syndax Pharmaceuticals (SNDX) | 0.3 | $23M | 1.0M | 22.36 | |
| Larimar Therapeutics (LRMR) | 0.3 | $22M | 1.5M | 14.61 | |
| Ikena Oncology (IKNA) | 0.3 | $21M | 750k | 28.25 | |
| Scpharmaceuticals (SCPH) | 0.3 | $18M | 2.7M | 6.65 | |
| Concert Pharmaceuticals I equity | 0.2 | $15M | 3.0M | 4.99 | |
| Cullinan Oncology (CGEM) | 0.2 | $15M | 350k | 41.67 | |
| Oric Pharmaceuticals (ORIC) | 0.2 | $14M | 584k | 24.50 | |
| Proqr Therapeutics N V Shs Euro (PRQR) | 0.2 | $14M | 2.1M | 6.61 | |
| Bctg Acquisition Corp | 0.2 | $14M | 1.3M | 11.12 | |
| Arya Sciences Acquisition Com Cl A | 0.2 | $13M | 971k | 13.78 | |
| Bcls Acquisition Corp Com Cl A | 0.2 | $13M | 1.3M | 10.57 | |
| Milestone Pharmaceuticals (MIST) | 0.2 | $13M | 2.2M | 5.79 | |
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.2 | $13M | 1.3M | 10.16 | |
| Repare Therapeutics Ord (RPTX) | 0.2 | $13M | 409k | 30.69 | |
| Ocular Therapeutix (OCUL) | 0.2 | $12M | 750k | 16.41 | |
| Arya Sciences Acqu Corp Iv Cl A (ARYD) | 0.2 | $11M | 1.0M | 10.47 | |
| Therapeuticsmd | 0.2 | $11M | 7.8M | 1.34 | |
| Frazier Lifesciences Acquisition Unit 12/09/2025 | 0.2 | $10M | 1.0M | 10.16 | |
| Fs Development Corp Ii Com Cl A | 0.2 | $10M | 1.0M | 9.96 | |
| Phasebio Pharmaceuticals (PHASQ) | 0.1 | $9.9M | 2.9M | 3.46 | |
| Cogent Biosciences (COGT) | 0.1 | $9.0M | 1.0M | 8.78 | |
| Kalvista Pharmaceuticals (KALV) | 0.1 | $9.0M | 350k | 25.69 | |
| 5 01 Acquisition Corp Com Cl A | 0.1 | $7.5M | 750k | 9.95 | |
| Helix Acquisition Corp Com Cl A | 0.1 | $7.1M | 700k | 10.21 | |
| Health Sciences Acq Corp 2 Ord Shs | 0.1 | $7.0M | 625k | 11.19 | |
| Syros Pharmaceuticals | 0.1 | $6.7M | 900k | 7.48 | |
| Miragen Therapeutics (VRDN) | 0.1 | $5.2M | 312k | 16.71 | |
| X4 Pharmaceuticals (XFOR) | 0.1 | $4.6M | 537k | 8.61 | |
| Imara | 0.0 | $2.1M | 249k | 8.44 | |
| Cerevel Therapeutics Hldng *w Exp 06/09/2027 (CEREW) | 0.0 | $1.0M | 233k | 4.31 |
